HAE
HealthcareHaemonetics Corporation · Medical - Instruments & Supplies · $3B
What is Haemonetics Corporation?
Haemonetics Corporation is a Boston-based medical technology company focused on blood management solutions. Operating across plasma collection, blood center operations, and hospital care, it serves a specialized corner of the healthcare market with both hardware and software products.
Haemonetics generates revenue by selling automated collection devices, single-use disposables, and integrated software platforms to plasma centers, blood banks, and hospitals. Its three segments — Plasma, Blood Center, and Hospital — each address distinct workflows. The Plasma segment supports donor management and supply chain operations. The Blood Center segment equips facilities that collect specific blood components. The Hospital segment delivers hemostasis monitoring systems and autologous blood recovery tools used during and after surgery.
Founded in 1991 and headquartered in Boston, Haemonetics has built its business around the full lifecycle of blood and plasma management.
- NexSys PCS and PCS2 automated plasmapheresis equipment and disposables
- NexLynk DMS donor management software platform
- TEG and ClotPro hemostasis analyzer systems for hospital use
- Cell Saver Elite+ autologous blood recovery system
- BloodTrack and SafeTrace Tx blood management software
Is HAE a Good Stock to Buy?
UQS Score rates HAE as Good overall, reflecting a balanced but mixed picture across its five evaluation pillars.
The Quality pillar comes in at a Good rating, suggesting the business generates reasonably dependable financial results relative to its mid-cap healthcare peers. Valuation is rated Attractive, meaning the stock does not appear richly priced compared to its fundamentals — a meaningful consideration for investors weighing entry points.
The Moat pillar registers as Weak, indicating that Haemonetics faces meaningful competitive pressure and may lack the durable pricing power seen in stronger healthcare franchises. Growth and Risk both sit at Neutral, suggesting neither a compelling expansion story nor significant near-term financial stress.
Pro members can view the complete pillar breakdown and underlying financial metrics behind HAE's UQS Score at uqs-score.com. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HAE pay dividends?
No — Haemonetics Corporation does not currently pay a dividend.
Haemonetics does not currently pay a dividend. For a medical technology company investing in product development across plasma, blood center, and hospital segments, retaining capital for R&D and operational expansion is a common strategic choice. Income-focused investors should factor this into their assessment when comparing HAE to dividend-paying healthcare peers.
When does HAE report earnings?
Haemonetics reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's results across its three segments — Plasma, Blood Center, and Hospital — tend to reflect trends in healthcare facility demand and disposable consumption rates. Segment mix shifts can meaningfully influence reported outcomes from quarter to quarter.
For the most recent quarter's results and guidance, visit Haemonetics Corporation's investor relations page directly.
HAE Price History
+6.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Haemonetics Corporation?
Based on Haemonetics Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HAE Long-term Outlook
With Growth rated Neutral and Risk also Neutral, Haemonetics presents a steady rather than high-velocity fundamental outlook. The Plasma and Hospital segments offer recurring revenue through disposables and software subscriptions, which can provide some stability. However, the Weak Moat rating suggests the company must continue investing to defend its market position against competitors with broader scale or deeper customer relationships. The Attractive Valuation rating may offer a degree of downside cushion if near-term growth remains modest.
Growth drivers
- Recurring disposable and software revenue tied to plasma and hospital workflows
- Expansion of hemostasis monitoring adoption in hospital settings
- Ongoing demand for plasma-derived therapies supporting collection center activity
Key risks
- Limited competitive moat may pressure pricing and customer retention
- Segment concentration risk if plasma collection volumes soften
- Execution risk in sustaining growth across three distinct business lines
HAE vs Peers
Haemonetics operates in a specialized segment of medical technology, where it competes with companies offering overlapping device, disposable, and software solutions.
Warby Parker operates in consumer eyewear rather than blood management, representing a different end of the healthcare device and services spectrum.
LeMaitre Vascular focuses on peripheral vascular surgery devices, serving a surgical niche that overlaps with Haemonetics' hospital-facing product lines.
ICU Medical provides infusion therapy and critical care products, competing with Haemonetics in hospital settings where fluid and blood management intersect.
Frequently Asked Questions
What does Haemonetics do?
Haemonetics designs and sells medical devices, disposables, and software for blood and plasma management. Its three business segments — Plasma, Blood Center, and Hospital — serve collection centers, blood banks, and clinical care teams. Products range from automated plasmapheresis equipment to hemostasis analyzers used during surgery.
Does HAE pay dividends?
No, Haemonetics does not currently pay a dividend. The company appears to prioritize reinvesting capital into its product portfolio and operational infrastructure across its three segments rather than returning cash to shareholders through distributions.
When does HAE report earnings?
Haemonetics follows a standard quarterly earnings cadence for US-listed companies. For precise reporting dates and the latest financial results, check the investor relations section of the Haemonetics corporate website.
Is HAE a good stock to buy?
HAE carries a Good overall UQS Score, with an Attractive Valuation and Good Quality rating working in its favor. The Weak Moat and Neutral Growth ratings temper the picture. Whether it fits your portfolio depends on your own risk tolerance and investment criteria — the full pillar breakdown is available to Pro members.
Is HAE overvalued?
The UQS Valuation pillar rates HAE as Attractive, suggesting the stock is not trading at a premium relative to its fundamentals. This does not guarantee price appreciation, but it indicates the current market price may offer reasonable value compared to the company's financial profile.
How does HAE compare to its competitors?
Among the peers tracked alongside HAE — including ICU Medical and LeMaitre Vascular — Haemonetics is distinguished by its focus on plasma collection and blood management workflows. Its combination of hardware, disposables, and software creates a more integrated offering than pure-device competitors, though its Weak Moat rating suggests differentiation remains a challenge.
What is HAE's market cap bracket?
Haemonetics is classified as a mid-cap company. This places it in a tier where it has meaningful operational scale but may lack the resources and brand recognition of large-cap medical technology leaders.
Who founded Haemonetics?
Haemonetics was founded in 1991. Detailed founding history, including the names of its original leadership, is publicly available through the company's official corporate history and press resources.
Is HAE a long-term quality stock?
As a long-term quality indicator, HAE's Good UQS Score reflects a business with reasonable financial characteristics but a Weak Moat that may limit compounding power over time. Long-term investors should weigh the Attractive Valuation against the competitive pressures flagged in the Moat pillar before committing capital.
What is the main competitive advantage of Haemonetics?
Haemonetics' primary advantage lies in its integrated approach — combining proprietary collection hardware, single-use disposables, and software platforms into end-to-end workflows for plasma and blood management. However, the UQS Moat pillar rates this advantage as Weak, suggesting competitors can and do challenge its positioning.
What sector does HAE belong to?
Haemonetics operates in the Healthcare sector, specifically within medical technology. It focuses on blood and plasma management — a specialized niche that intersects device manufacturing, consumables supply, and healthcare software.
Unlock Full HAE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare HAE against sector peers on key quality indicators
- ✓See valuation context relative to mid-cap healthcare peers
- ✓Get the complete analyst-style breakdown in one view
Pro Analysis
HAE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 17, 2026 | 50.3 | 59.1 | 39.0 | 29.5 | 41.4 | 91.0 | -6.0 |
| May 7, 2026 | 56.3 | 71.1 | 39.0 | 44.8 | 42.3 | 90.1 | +0.5 |
| May 3, 2026 | 55.8 | 71.1 | 39.0 | 44.8 | 42.3 | 86.5 | +0.1 |
| Apr 26, 2026 | 55.7 | 71.1 | 39.0 | 44.8 | 42.3 | 86.0 | +0.1 |
| Apr 23, 2026 | 55.6 | 71.1 | 39.0 | 44.8 | 42.3 | 85.1 | 0.0 |
| Apr 19, 2026 | 55.6 | 71.1 | 39.0 | 44.8 | 42.3 | 85.6 | -0.2 |
| Apr 18, 2026 | 55.8 | 71.1 | 39.0 | 44.8 | 42.3 | 86.9 | -0.5 |
| Apr 14, 2026 | 56.3 | 71.1 | 39.0 | 44.8 | 42.3 | 89.8 | -0.2 |
| Apr 12, 2026 | 56.5 | 71.1 | 39.0 | 44.8 | 42.3 | 91.5 | -0.1 |
| Apr 8, 2026 | 56.6 | 71.1 | 39.0 | 44.8 | 42.3 | 91.9 | 0.0 |
HAE — Pillar Breakdown
Quality
— 59.1/100 (25%)Haemonetics Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 29.5/100 (20%)Haemonetics Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 41.4/100 (15%)Haemonetics Corporation has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 84.2/100 (15%)Haemonetics Corporation appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 39/100 (25%)Haemonetics Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HAE.
Score Composition
Financial Data
More Stock Analysis
How is the HAE UQS Score Calculated?
The UQS (Unified Quality Score) for Haemonetics Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Haemonetics Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Haemonetics Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.